Sign In
Buy KIO
$11.18
-0.0300 (-0.268%)
At Close: Jun 22, 2026
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
07:00am, Thursday, 18'th Jun 2026
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase
KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share
04:25pm, Monday, 08'th Jun 2026
NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fu
KIO: High Beta Fixed Income CEF With Significant Downside (Rating Downgrade)
11:45am, Friday, 17'th Apr 2026
KKR Income Opportunities (KIO) is rated 'Sell' due to high beta, credit risk, and limited upside in the current macro environment. KIO's portfolio is now 50% single-B, 20% CCC, with a 50/50 split betw
KKR Income Opportunities Fund (NYSE:KIO) Stock Crosses Above 50-Day Moving Average – Here’s What Happened
03:27am, Friday, 17'th Apr 2026
Shares of KKR Income Opportunities Fund (NYSE: KIO - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $11.21 and traded as
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
07:00am, Tuesday, 14'th Apr 2026
Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medi
7 High-Yield Fixed Income CEFs Trading At Wide Discounts
07:37am, Monday, 13'th Apr 2026
Seven high-yield fixed income CEFs—ARDC, BGH, BIT, GHY, KIO, OPP, WDI—currently trade at wider-than-average discounts, offering yields from 10% to 14%. Market fears over private credit and macroec
KKR Income Opportunities Fund (NYSE:KIO) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?
04:09am, Wednesday, 01'st Apr 2026
KKR Income Opportunities Fund (NYSE: KIO - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $
KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share
05:23pm, Tuesday, 10'th Mar 2026
NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fu
KIO: Limited Growth Catalysts But Solid Income Fund
03:22pm, Monday, 02'nd Feb 2026
KKR Income Opportunities Fund is rated a hold, offering a 12.6% yield but lacking clear near-term catalysts. KIO trades at a 6.38% discount to NAV, with performance hampered by disappointing 2025 earn
KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share
04:47pm, Wednesday, 07'th Jan 2026
NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fu
KKR Income Opportunities Fund (NYSE:KIO) Short Interest Update
04:47am, Sunday, 28'th Dec 2025
KKR Income Opportunities Fund (NYSE: KIO - Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 119,058 shares,
KIO: High-Yield, But Dropping Distribution Coverage Due To Floating Rate Tilt
03:29pm, Wednesday, 17'th Dec 2025
KKR Income Opportunities Fund offers investors exposure to high yield through both floating- and fixed-rate income instruments. The fund has paid a relatively stable distribution for a number of years
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
06:45am, Monday, 01'st Dec 2025
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on
KKR Income Opportunities Fund (NYSE:KIO) Shares Pass Below 200-Day Moving Average – Here’s Why
03:40am, Wednesday, 19'th Nov 2025
KKR Income Opportunities Fund (NYSE: KIO - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $12.33 and traded as lo
KIO: A Real-Income 12% Yield Powered By KKR's Private Credit Machine
09:56am, Monday, 17'th Nov 2025
KKR Income Opportunities Fund (KIO) offers a 12% yield backed by real income from exclusive, privately negotiated loans via KKR's institutional credit platform. KIO's portfolio blends floating-rate lo
